A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy

Wang, Hairong; Zhang, Yawen; Zeng, Xiangle; Pei, Wenjie; Fan, Rong; Wang, Yushuai; Wang, Xiu; Li, Jianchun

doi:10.2147/ijn.s299681

Cited by 12 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rosiglitazone maleate has traditionally been widely used to reduce sugar in the blood of patients with diabetes mellitus (Zhao et al, 2021). However, investigators have recently demonstrated that rosiglitazone maleate also has a therapeutic effect on various cancers, including lung cancer, breast cancer, and pancreatic cancer (Dang et al, 2018;Wang et al, 2020;Wu et al, 2020;Wang et al, 2021;Zhou et al, 2021). We found that rosiglitazone maleate had a significant therapeutic effect on RD cells and inhibited RD cell proliferation by mediating the PPARG pathway.…”

Section: Discussionmentioning

confidence: 68%

Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation via PPARG

Pan

Lou

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Background: Rhabdomyosarcoma (RMS) is one of the most common types of soft-tissue sarcomas in children, and it exhibits a low 5-years survival rate. The survival outcome has shown no significant improvements in the past 30 years miRNA profiling of RMS might therefore provide a novel insight into uncovering new molecular targets for therapy.Methods: We analyzed miRNA and RNA sequencing data from patients and the TARGET database to reveal the potential miRNA-mRNA axes and validated them in patients’ samples. After the miRNA antagomirs were used to silence the target miRNAs in the cell model, qRT-PCR, western immunoblotting analysis, and proliferation assays were performed to explore the interaction between miR-130a/b and peroxisome proliferator-activated receptor gamma (PPARG) and their effects.Results: In RMS patients, the expression of miR-130a/b was augmented, and its related PPARG gene was suppressed. Bioinformatics analysis showed that miR-130a/b targeted the PPARG gene and inhibited the proliferation of human RMS cell lines. In addition, rosiglitazone maleate activated the expression of PPARG in human RMS cell lines to suppress proliferation.Conclusion: miR-130a/b regulates the malignant process in RMS by targeting PPARG. Furthermore, the PPARG agonist rosiglitazone maleate attenuated the proliferation of RD cells and might therefore be of benefit to RMS patients.

show abstract

Section: Discussionmentioning

confidence: 68%

Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation via PPARG

Pan

Lou

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…HA-DAS polymer was synthesized by our research group and the structure was confirmed by 1 H-NMR. 37 In short, EDCI and DMAP were used to activate the carboxyl group of HA in deionized water, and then DAS was added to form the HA-DAS polymer by ester bond.…”

Section: Methodsmentioning

confidence: 99%

“…HDO-NPs were hydrolyzed by strong alkaline hydrolysis to determine the drug loading and encapsulation efficiency of DAS and OLA. 37 , 38 In short, 4 mg HDO-NPs were dissolved in 1 mL deionized water, 100 μL NaOH (1 mol/L) was added for 0.5 h, and then 100 μL HCl (1 mol/L) was added for neutralization. Subsequently, 3 mL methanol was added to dissolve the cracked DAS and OLA, which were mixed evenly and centrifuged (5000 rpm, 10 min).…”

Section: Methodsmentioning

confidence: 99%

pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy

Zeng¹,

Wang²,

Zhang³

et al. 2022

IJN

Self Cite

View full text Add to dashboard Cite

Purpose This study emphasized that dasatinib (DAS) and olaparib (OLA) have synergistic effects on triple negative breast cancer, by inducing DNA damage and inhibiting DNA damage repair. However, poor water solubility, short half-life of drugs, and low drug concentration in tumor tissue limit the clinical application. Methods In this research, acid-sensitive ester bonds were used to connect hydrophobic DAS and hydrophilic hyaluronic acid (HA) to form the amphiphilic polymer prodrug HA-DAS, and then OLA was added as the core, the HA-DAS was used as the carrier to form nanomicelles (HDO-NPs) in aqueous. The characterization and drug release of HDO-NPs were studied, and the cytotoxicity, targeting effect, and intracellular transport behavior of HDO-NPs were evaluated in MDA-MB-231. In addition, the pharmacokinetic and therapeutic effect of HDO-NPs were further verified in vivo. Results In vitro characterizations showed that HDO-NPs were spherical with uniform particle size, good stability and anti-dilution ability, and displayed favorable pH-responsive drug release behavior. In addition, the cell experiments showed that HDO-NPs could be effectively taken up by binding to the overexpressed CD44 proteins of MDA-MB-231 cells, resulting in increased intracellular drug concentration. In vivo experiments showed that HDO-NPs can effectively target tumor tissues, have excellent therapeutic effects on tumor, significantly prolong the circulation time of drugs in vivo, and effectively improved the bioavailability of drugs. Conclusion DAS and OLA were designed into micelles, the efficacy of HDO-NPs was higher than that of free drugs. Therefore, HDO-NPs have good application prospects in the treatment of triple negative breast cancer.

show abstract

“…The developed THDR-NPs showed better efficacy than the taking of free TKIs. In addition, the capacity of THDR-NPs to prevent tumor metastasis has been demonstrated (58). Another study using micelle nanoparticles to deliver anlotinib also showed a more effective uptake to the melanoma cells (59).…”

Section: Nanotechnology As the Potential Delivery Systemmentioning

confidence: 97%

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

et al. 2021

View full text Add to dashboard Cite

Targeted therapies such as oral tyrosine kinase inhibitors (TKIs) are the main therapeutic strategy effective for advanced hepatocellular carcinoma (HCC). Currently six tyrosine kinase inhibitors for HCC therapy have been approved. The newly approved first-line drug donafenib represent the major milestones in HCC therapeutics in recent years. However, drug resistance in HCC remains challenging due to random mutations in target receptors as well as downstream pathways. TKIs-based combinatorial therapies with immune checkpoint inhibitors such as PD-1/PD-L1 antibodies afford a promising strategy to further clinical application. Recent developments of nanoparticle-based TKI delivery techniques improve drug absorption and bioavailability, enhance efficient targeting delivery, prolonged circulation time, and reduce harmful side effects on normal tissues, which may improve the therapeutic efficacy of the TKIs. In this review, we summarize the milestones and recent progress in clinical trials of TKIs for HCC therapy. We also provide an overview of the novel nanoparticle-based TKI delivery techniques that enable efficient therapy.

show abstract

A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy

Cited by 12 publications

References 33 publications

Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation via PPARG

Down-Regulated miR-130a/b Attenuates Rhabdomyosarcoma Proliferation via PPARG

pH-Responsive Hyaluronic Acid Nanoparticles for Enhanced Triple Negative Breast Cancer Therapy

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials

Contact Info

Product

Resources

About